Search for other papers by Fizzah Iqbal in
Google Scholar
PubMed
Search for other papers by William Adams in
Google Scholar
PubMed
Search for other papers by Ioannis Dimitropoulos in
Google Scholar
PubMed
Search for other papers by Samiul Muquit in
Google Scholar
PubMed
Search for other papers by Daniel Flanagan in
Google Scholar
PubMed
.21–10.82 Proportion requiring oestrogen replacement 4/15 3/14 0.75 1 0.14–4.17 Proportion requiring desmopressin 3/31 1/19 2.04 1.0 0.20–21.07 Proportion taking dopamine agonist 3/33 4/22 0.29 0.20 0
Search for other papers by Anastasia P Athanasoulia-Kaspar in
Google Scholar
PubMed
Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Ludwig-Maximilians-Universität München, Munich, Germany
Search for other papers by Matthias K Auer in
Google Scholar
PubMed
Search for other papers by Günter K Stalla in
Google Scholar
PubMed
Search for other papers by Mira Jakovcevski in
Google Scholar
PubMed
human GH; 51 (44.3%) suffered from gonadotropic insufficiency and 67 (58.3%) were hypothyroid (all on levothyroxine replacement), whereas 18 presented with diabetes insipidus and were under substitution with desmopressin and 52 patients were diagnosed
Department of Clinical Chemistry, Karolinska University Hospital, Stockholm, Sweden
Search for other papers by Anna Sjöström in
Google Scholar
PubMed
Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden
Search for other papers by Susanne Rysz in
Google Scholar
PubMed
Center for Neurology, Academic Specialist Center, Stockholm, Sweden
Search for other papers by Henrik Sjöström in
Google Scholar
PubMed
Department of Endocrinology, Karolinska University Hospital, Stockholm, Sweden
Search for other papers by Charlotte Höybye in
Google Scholar
PubMed
, synthetic AVP (desmopressin) is used as procoagulant treatment, for example, in von Willebrand’s disease (vWD), as it increases platelet release of coagulation factor VIII and von Willebrand factor after administration. During admission when the patients
Search for other papers by Mikkel Andreassen in
Google Scholar
PubMed
Search for other papers by Anders Juul in
Google Scholar
PubMed
Search for other papers by Ulla Feldt-Rasmussen in
Google Scholar
PubMed
Search for other papers by Niels Jørgensen in
Google Scholar
PubMed
Craniopharyngioma 1 Medulla blastoma 1 Hypophysitis 1 Hormone substitution Thyroxine 5 Hydrocortisone 5 Growth hormone 1 Desmopressin 1 Other treatments Somatostatin analogs 2
Clinical Institute, University of Southern Denmark, Odense C, Denmark
Search for other papers by Morten Winkler Møller in
Google Scholar
PubMed
Department of Endocrinology, Odense University Hospital, Odense C, Denmark
Search for other papers by Marianne Skovsager Andersen in
Google Scholar
PubMed
Clinical Institute, University of Southern Denmark, Odense C, Denmark
Search for other papers by Christian Bonde Pedersen in
Google Scholar
PubMed
Department of Pathology, Odense University Hospital, Odense C, Denmark
Search for other papers by Bjarne Winther Kristensen in
Google Scholar
PubMed
Clinical Institute, University of Southern Denmark, Odense C, Denmark
Search for other papers by Frantz Rom Poulsen in
Google Scholar
PubMed
insipidus Four patients had DI preoperatively. In one patient, this disappeared after surgery. Overall, 18% (12/67) patients required postsurgical desmopressin treatment permanently in the iMRI group vs 23% (26/113) in the control group. Transient
Department of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark
Search for other papers by Mette Marie Baunsgaard in
Google Scholar
PubMed
Department of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark
Search for other papers by Anne Sophie Lind Helligsoe in
Google Scholar
PubMed
Department of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark
Search for other papers by Louise Tram Henriksen in
Google Scholar
PubMed
Department of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark
Search for other papers by Torben Stamm Mikkelsen in
Google Scholar
PubMed
Search for other papers by Michael Callesen in
Google Scholar
PubMed
Search for other papers by Britta Weber in
Google Scholar
PubMed
Department of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark
Search for other papers by Henrik Hasle in
Google Scholar
PubMed
Department of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark
Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark
Search for other papers by Niels Birkebæk in
Google Scholar
PubMed
.7 (12.5–12.9) Current hormone replacement therapy other that GH Sex hormones a 12 29 1 5 Desmopressin 3 7 0 0 Thyroid hormone 18 44 1 5 Hydrocortisone 8 20 0 0 Age
Department of Medicine, Division of Endocrinology and Centre for Endocrine Tumors, Leiden University Medical Centre, Leiden, The Netherlands
Department of Neurosurgery, University Neurosurgical Centre Holland (UNCH), Leiden University Medical Centre, Haaglanden Medical Centre and Haga Teaching Hospitals, Leiden and The Hague, The Netherlands
Search for other papers by Amir H Zamanipoor Najafabadi in
Google Scholar
PubMed
Search for other papers by Merel van der Meulen in
Google Scholar
PubMed
Search for other papers by Ana Luisa Priego Zurita in
Google Scholar
PubMed
Search for other papers by S Faisal Ahmed in
Google Scholar
PubMed
Search for other papers by Wouter R van Furth in
Google Scholar
PubMed
Search for other papers by Evangelia Charmandari in
Google Scholar
PubMed
Search for other papers by Olaf Hiort in
Google Scholar
PubMed
Search for other papers by Alberto M Pereira in
Google Scholar
PubMed
Search for other papers by Mehul Dattani in
Google Scholar
PubMed
Search for other papers by Diana Vitali in
Google Scholar
PubMed
Search for other papers by Johan P de Graaf in
Google Scholar
PubMed
Search for other papers by Nienke R Biermasz in
Google Scholar
PubMed
insipidus separately, while only three studies provided a definition for permanent diabetes insipidus. One study defined it as the need for desmopressin for a minimum of 2 months, and another study used a 3 months timeframe. Four studies reported the
Search for other papers by Lukas Plachy in
Google Scholar
PubMed
Search for other papers by Petra Dusatkova in
Google Scholar
PubMed
Search for other papers by Klara Maratova in
Google Scholar
PubMed
Search for other papers by Shenali Anne Amaratunga in
Google Scholar
PubMed
Search for other papers by Dana Zemkova in
Google Scholar
PubMed
Search for other papers by Vit Neuman in
Google Scholar
PubMed
Search for other papers by Stanislava Kolouskova in
Google Scholar
PubMed
Search for other papers by Barbora Obermannova in
Google Scholar
PubMed
Search for other papers by Marta Snajderova in
Google Scholar
PubMed
Search for other papers by Zdenek Sumnik in
Google Scholar
PubMed
Search for other papers by Jan Lebl in
Google Scholar
PubMed
Search for other papers by Stepanka Pruhova in
Google Scholar
PubMed
random sample or during a water deprivation test that adequately responded to desmopressin administration ( 19 ). The heights of all study participants were measured to the nearest 1 mm. Data regarding birth parameters, previous height development
Search for other papers by Liza Das in
Google Scholar
PubMed
Search for other papers by Kim Vaiphei in
Google Scholar
PubMed
Search for other papers by Ashutosh Rai in
Google Scholar
PubMed
Search for other papers by Chirag Kamal Ahuja in
Google Scholar
PubMed
Search for other papers by Paramjeet Singh in
Google Scholar
PubMed
Search for other papers by Ishani Mohapatra in
Google Scholar
PubMed
Search for other papers by Rajesh Chhabra in
Google Scholar
PubMed
Search for other papers by Anil Bhansali in
Google Scholar
PubMed
Search for other papers by Bishan Dass Radotra in
Google Scholar
PubMed
Green Templeton College, University of Oxford, Oxford, UK
Search for other papers by Ashley B Grossman in
Google Scholar
PubMed
Search for other papers by Márta Korbonits in
Google Scholar
PubMed
Search for other papers by Pinaki Dutta in
Google Scholar
PubMed
. Histopathology showed a pituicytoma ( Fig. 3A , B , C and D ). The patient developed permanent DI which was managed with intranasal desmopressin. Post-operative MRI did not show any residual tumour. He is doing well without any residual disease documented on
Search for other papers by Ruth Percik in
Google Scholar
PubMed
Search for other papers by Sherwin Criseno in
Google Scholar
PubMed
Search for other papers by Safwaan Adam in
Google Scholar
PubMed
Search for other papers by Kate Young in
Google Scholar
PubMed
Royal Marsden Hospital, London, UK
Search for other papers by Daniel L Morganstein in
Google Scholar
PubMed
urine volume greater than 50 mg/kg body weight; water deprivation test revealing diluted urine (osmolality below 100) when serum osmolality exceeds 295 mOsm/kg, followed by a desmopressin challenge leading to urine concentration above 300 mOsm